| 2.22 -0.04 (-1.77%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.77 | 1-year : | 3.1 |
| Resists | First : | 2.37 | Second : | 2.65 |
| Pivot price | 2.33 |
|||
| Supports | First : | 1.93 | Second : | 1.6 |
| MAs | MA(5) : | 2.31 |
MA(20) : | 2.28 |
| MA(100) : | 1.83 |
MA(250) : | 1.06 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 43.3 |
D(3) : | 49.5 |
| RSI | RSI(14): 46.8 |
|||
| 52-week | High : | 3.03 | Low : | 0.43 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ IPSC ] has closed above bottom band by 25.7%. Bollinger Bands are 40.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.3 - 2.32 | 2.32 - 2.33 |
| Low: | 2.16 - 2.17 | 2.17 - 2.19 |
| Close: | 2.19 - 2.22 | 2.22 - 2.24 |
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Sat, 25 Apr 2026
Century Therapeutics (NASDAQ:IPSC) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Fri, 24 Apr 2026
Century Therapeutics: A Biotech With Interesting Optionality Opportunities (NASDAQ:IPSC) - Seeking Alpha
Thu, 23 Apr 2026
What is HC Wainwright's Estimate for IPSC Q1 Earnings? - MarketBeat
Fri, 10 Apr 2026
Century Therapeutics (IPSC) director Martin Patrick Murphy files initial Form 3 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 180 (M) |
| Shares Float | 98 (M) |
| Held by Insiders | 12.8 (%) |
| Held by Institutions | 58.7 (%) |
| Shares Short | 10,290 (K) |
| Shares Short P.Month | 6,330 (K) |
| EPS | -0.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.82 |
| Profit Margin | -8.8 % |
| Operating Margin | -13.8 % |
| Return on Assets (ttm) | -3.3 % |
| Return on Equity (ttm) | -6 % |
| Qtrly Rev. Growth | -100 % |
| Gross Profit (p.s.) | 0.07 |
| Sales Per Share | 0.6 |
| EBITDA (p.s.) | -0.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -104 (M) |
| Levered Free Cash Flow | -97 (M) |
| PE Ratio | -15.86 |
| PEG Ratio | 0 |
| Price to Book value | 1.21 |
| Price to Sales | 3.65 |
| Price to Cash Flow | -3.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|